secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001213900-24-094622
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actinium appoints June Almenoff, M.D., Ph.D. to Board of Directors
------------------------------------------------------------------

- Dr. Almenoff brings over 25 years of biopharma leadership; previously President and CMO of Furiex (acquired by Actavis/AbbVie for $1.2B).
- She will serve on the Nominating and Corporate Governance Committee; term as Class III director expires at 2025 annual meeting.
- Granted options for 50,000 shares at $1.71, vesting 28% at 12 months then 2% monthly thereafter.
- Appointment effective November 1, 2024; experienced in translational medicine, clinical development, and regulatory submissions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390024094622/0001213900-24-094622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390024094622/ea022011301-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-094622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer